HomeProductsBioactive CompoundsEndocrine & Hormonal TargetsAndrogen ReceptorDarolutamide
Chemical structure of CAS 1297538-32-9

Darolutamide

CAS No.1297538-32-9
MDL No.MFCD29472270
MFC19H19ClN6O2
MW398.80
InChI KeyBLIJXOOIHRSQRB-PXYINDEMSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1297538-32-9
Product NameDarolutamide

Biological Targets

AR

Associated Conditions

prostate cancer·breast cancer·prostate adenocarcinoma·prostate carcinoma·maligant granulosa cell tumor of ovary·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by darolutamide: Prediction of in vivo drug-drug interactions.

Chemico-biological interactions • Vol. 403 • 2024
PMID: 39278459DOI: 10.1016/j.cbi.2024.111246

Darolutamide-mediated phospholipid remodeling induces ferroptosis through the SREBP1-FASN axis in prostate cancer.

International journal of biological sciences • Vol. 20, Issue 12 • 2024
PMID: 39309439PMC: PMC11414384DOI: 10.7150/ijbs.101039

Darolutamide does not interfere with OATP-mediated uptake of docetaxel.

International journal of cancer • Vol. 155, Issue 2 • 2024
PMID: 38491867DOI: 10.1002/ijc.34922

Darolutamide For Castration-Resistant Prostate Cancer.

OncoTargets and therapy • Vol. 12 • 2019
PMID: 31695432PMC: PMC6816030DOI: 10.2147/OTT.S197244

Documentation